Everen Group Promotes Karyn Peixoto to Chief HR Officer
The Everen Group is pleased to announce the promotion of Karyn Peixoto to the role of Senior Vice President, Chief Human Resources Officer, based in the Bermuda office, effective April 1, 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250331475520/en/
Karyn Peixoto, Everen Group
Since joining the Everen Group in December 2022 as VP HR & Administration, Karyn has been instrumental in shaping the Group’s people strategies, building a strong company culture, and leading initiatives to attract, develop, and retain top talent.
In her expanded role as part of the Executive Leadership Team, Ms. Peixoto will continue to lead the company’s HR function with a focus on aligning people strategies with the Group’s business objectives, working with the Executive Leadership Team to develop and deliver strategic initiatives, driving employee engagement, and fostering a high-performing workplace.
Commenting on her promotion, Robert Foskey, President & CEO of the Everen Group, said: “Karyn’s promotion is a well-earned recognition of her leadership and significant contributions to the Group, positioning us well for long-term success in the energy insurance market.
“Her considerable experience, together with her sound judgment and leadership skills, have been pivotal in building a strong team at the Everen Group. She brings a strategic mindset and tremendous energy to her role, as well as a deep commitment to creating a positive work environment for our employees.”
About Everen Group:
The Everen Group – a group of leading energy insurance companies based in Bermuda – includes two distinct operating companies providing complementary products: Everen and Everen Specialty. Everen is the largest energy insurance mutual company in the world, operating for over 50 years and acting as a pure mutual owned by its member shareholders. Its underwriting is 100% supported by its own balance sheet with no third-party capital and it offers up to $450 million of per occurrence limits. Everen Specialty is an industry owned commercial (re)insurer offering property and casualty insurance and reinsurance for members and non-members. Everen Specialty also has a subsidiary, OCIL Specialty, Ltd (OSL), writing U.S. surplus lines business through OSL Insurance Services (OISI), a managing general agent based in Houston, Texas.
For further information about the Everen Group, please visit www.everengroup.bm
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331475520/en/
Contacts
For inquiries regarding this press release, please contact:
Elizabeth Deacon, Communications Manager on elizabeth.deacon@everengroup.bm
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frontgrade Gaisler Launches New GRAIN Line and Wins SNSA Contract to Commercialize First Energy-Efficient Neuromorphic AI for Space Applications2.4.2025 09:00:00 EEST | Press release
The Swedish National Space Agency (SNSA) has awarded Frontgrade Gaisler, a leading provider of radiation-hardened microprocessors for space missions, a contract to commercialize the first neuromorphic System on Chip (SoC) device for space applications. Already in development at Frontgrade Gaisler, the device is part of the company’s new GRAIN (Gaisler Research Artificial Intelligence NOEL-V) product line. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250401194593/en/ Frontgrade Gaisler, a leading provider of radiation-hardened microprocessors for space missions, has launched its new Gaisler Research Artificial Intelligence NOEL-V (GRAIN) product line. The first GRAIN device to premiere – the Gr801 SoC – integrates Akida™ neuromorphic technology from BrainChip, the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI. The first GRAIN device that Frontgrade Gaisler will premiere –
Allshares Acquires Bolago to Strengthen Global Leadership and Expand Equity Management Offering2.4.2025 08:00:00 EEST | Press release
Allshares, a leading provider of equity and incentive management solutions, today announced the acquisition of Bolago, a company offering digital solutions for share programs, option schemes, and investments. The acquisition reinforces Allshares’ position as a leading global platform for end-to-end equity plan management and expands its capabilities in supporting growth-stage businesses and entrepreneurs. The deal follows Allshares’ recently announced accelerated growth strategy and builds on its global momentum. By integrating Bolago’s advanced technology for scenario planning and equity modeling, Allshares will broaden its product offering and further empower companies to manage incentive programs at scale. Hannes Rosén, CEO of Bolago, shared his excitement about the partnership: “Over the years, we’ve built a strong and diverse customer base and a talented team. Joining Allshares is a unique opportunity to elevate our service delivery with tech-forward compensation and equity softwa
Desentum Reports Strong Safety and Immunological Data From Phase 1 Clinical Study With Investigational Birch Pollen Allergy Vaccine DM-101PX2.4.2025 07:20:00 EEST | Press release
Desentum Oy, a clinical-stage biopharmaceutical company developing novel immunotherapies for treating allergies, announces positive clinical data with birch pollen allergy vaccine DM-101PX. The short-course treatment was found to be safe and well tolerated in birch pollen allergic patients and to induce a very strong and sustained allergen-specific IgG4 response. DM-101PX-induced immunoglobulins were found to efficiently block IgE-mediated basophil activation endorsing the product’s potential to induce a protective immune response. The randomised, double-blind, placebo-controlled study evaluated three dose escalation regimens, each consisting of ten subcutaneous injections over 10 weeks with DM-101PX or placebo in a total of thirty birch pollen allergic adults. No serious or severe adverse events occurred, and most adverse events were local injection-site reactions that are typically seen in subcutaneous allergen immunotherapy. Nearly all patients reached their targeted maximum dose. T
GE HealthCare and FPT Expand Strategic Partnership to Drive AI-Powered Healthcare Innovation2.4.2025 07:06:00 EEST | Press release
Global IT firm FPT and GE HealthCare announced a Strategic Cooperation Agreement, expanding their commercial alliance to advance product strategy and development, and establish an FPT Competency Center in Vietnam. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250401306987/en/ This deepening collaboration reflects a strategic shift from project-based engagement to a long-term alliance aimed at accelerating the adoption of AI-driven solutions, enhancing operational efficiency, and improving patient care. As part of the commercial alliance, FPT will become a channel partner for GE HealthCare, jointly promoting and delivering GE HealthCare’s digital solutions in Vietnam and throughout its country network. FPT also plans on collaborating with GE HealthCare’s Science & Technology Office and affiliates to co-develop new and further develop GE HealthCare’s existing and new digital healthcare products. A key highlight of the partner
Former Mitsubishi IP Leader to Head Sisvel Japan2.4.2025 07:00:00 EEST | Press release
Yoshinori Shimizu has become managing director of the Japanese office of Sisvel, Europe’s biggest and longest-established patent pool operator. The appointment coincides with the retirement of Tetsuro Fuse, who will continue to work with Sisvel in an advisory capacity. Mr Shimizu is widely acknowledged as one of Japan’s leading IP professionals and most recently served as Deputy General Manager of the Corporate Export Control Division at Mitsubishi Electric Corporation, where he worked for 29 years. During his time at Mitsubishi, Mr Shimizu was instrumental in shaping the company’s global IP strategy, negotiating patent licensing agreements and resolving disputes. He has also played a key role in several patent pool initiatives, including those operated by Sisvel. As managing director of Sisvel Japan, Mr Shimizu will work closely with Sisvel’s global leadership team to drive the continued growth of the firm’s licensing programmes in Japan and across Asia. “Having worked with Sisvel as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom